Clinical Trials Directory

Trials / Completed

CompletedNCT06537518

The Difference Between Using Local and General Dexamethasone in Arthroscopic Anterior Cruciate Ligament Repair

Adductor Canal Block With Dexamethasone Versus Adductor Canal Block With Systemic Dexamethasone in Arthroscopic Anterior Cruciate Ligament Repair

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
123 (actual)
Sponsor
Benha University · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Arthroscopic knee injuries, such as the anterior cruciate ligament (ACL) injury, are common and often result in postoperative pain. Regional anesthetic techniques, such as femoral nerve block (FNB) and adductor canal block (ACB), can help alleviate pain and reduce opioid consumption. ACB, which blocks the saphenous nerve and obturator nerve branches, is preferred over FNB due to its potential to decrease mobility and increase falls risk. Dexamethasone, a potent glucocorticoid, is used as an adjuvant for ACB, but its perineural administration may carry neurotoxicity risks. Some pain physicians prefer intravenous administration to prolong the action of local anesthetics used in peripheral nerve blocks.

Conditions

Interventions

TypeNameDescription
DRUGDexamethasone injectionDexamethasone, a potent glucocorticoid, decreases the inflammatory response, tissue damage, and pain after surgical procedures; which can be injected locally or Intravenously.
DRUGBupivacaine 0.375% Injectable SolutionIsobaric bupivacaine (0.375%) is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
DRUGBupivacaine 0.5% Injectable Solution20 ml of Bupivacain 0.5% was mixed with dexamethasone 8 mg is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.

Timeline

Start date
2022-05-01
Primary completion
2022-11-20
Completion
2022-12-25
First posted
2024-08-05
Last updated
2024-08-05

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06537518. Inclusion in this directory is not an endorsement.